Indications
Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Composition
- Active substance
- vosoritide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Voxzogo
- Active substance
- vosoritide
- ATC code
- M05BX
- Therapeutic area
- Achondroplasia
- Marketing authorisation holder
- BioMarin International Limited
- Status
- Authorised
- EU authorisation